Antivirals reduce long COVID incidence at 90 days in patients with rheumatic diseases

CHICAGO — Patients with autoimmune and rheumatic diseases who received antiviral therapy for COVID-19 demonstrated reduced incidence of long COVID symptoms at 90 days post infection, according to data presented at ACR Convergence 2025.“Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection, as well as the risk for post-acute sequelae